Depression is a massive topic for the AKT, but NICE breaks it down into a very logical "stepped care" approach. Before we dive into the management, we usually start by quantifying the severity using the PHQ-9 (Patient Health Questionnaire-9).

The PHQ-9 is a self-report tool that screens for the frequency of depressive symptoms over the last 2 weeks. It's super helpful because it gives us a score that maps directly onto the severity of the episode.

I've put together a quick reference table for the PHQ-9 scores so you can see how they categorize severity.

Once we have a score, we follow the NICE Stepped Care Model. The idea is to provide the least intrusive, most effective intervention first, and then "step up" if the patient doesn't improve.

For mild depression, we often start with "low-intensity" psychological interventions like guided self-help or group CBT before jumping straight to meds. However, if the depression is moderate to severe, or if mild depression has persisted for a long time, that's when we bring in the "high-intensity" stuff like individual CBT and antidepressants.

Here is a breakdown of how those steps look in practice.

When it comes to Antidepressant Selection, the first-line choice is almost always a Selective Serotonin Reuptake Inhibitor (SSRI). They have a better safety profile and are generally better tolerated than older drugs like TCAs.

Here are the high-yield "rules of thumb" for the AKT:

• First-line: Sertraline, Citalopram, or Fluoxetine.
• Post-MI / Cardiac disease: ==Sertraline is the drug of choice== because it's the safest in cardiac patients.
• Children and Young People: ==Fluoxetine== is the only SSRI licensed for those under 18.
• Monitoring: Review patients within 2 weeks of starting (or 1 week if they are under 30 or at high risk of suicide).
• Switching: If there's no response after 4-6 weeks at a therapeutic dose, we usually switch to a different SSRI or a different class like Mirtazapine or Venlafaxine.

I'll pull up some detailed lessons on these guidelines so you can dive deeper into the specifics of each drug class and the switching protocols.

One last thing to keep in mind for the AKT is the risk of Serotonin Syndrome (especially if combining SSRIs with other serotonergic drugs like St John's Wort or MAOIs) and Discontinuation Syndrome.

Mnemonic: FINISH (Discontinuation Syndrome) Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances (brain zaps!), Hyperarousal.

To avoid this, we always taper antidepressants over at least 4 weeks (except for Fluoxetine, which has a very long half-life).

Would you like to try a quick game to see if you can categorize these different management steps and drug choices? It's a great way to make sure the "stepped care" logic is really sticking!